VivoSeq
Musculoskeletal

Sarcopenia

27

Pipeline Programs↗

22

Active Trials↗

20

Companies Involved↗

Sarcopenia is an emerging landscape with 27 programs across 20 companies. The most active players are Sanofi, Watson Pharmaceuticals, Novartis. 6 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

39/100

Mech. Concentration

13/100

Completion Rate

80/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

Phase 1W

Watson Pharmaceuticals

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2T

TNF Pharmaceuticals, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical6

Sorafenib

Bayer

Tadalafil

Eli Lilly

Gnrh Agonist

Johnson & Johnson

Testosterone Supplementation

Paracelsus Medical University

Gut Microbiota

Shanghai Jiao Tong University School of Medicine

Phase 15

Sodium Nitroprusside

Watson Pharmaceuticals

L-NMMA

National Heart, Lung, and Blood Institute (NHLBI)

Cetylpyridinium Chloride

Sanofi

Insulin Regular

The University of Texas Medical Branch, Galveston

BPM31510

BPGbio

Phase 28

Nandrolone Decanoate

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Bimagrumab

Novartis

PLH-2301

Pluto Inc.

AMC6156

Animuscure Inc.

REGN1033

Regeneron

Phase 32

Semaglutide

Novo Nordisk

Ophiochepalus Striatus Extract

Universitas Sriwijaya

Approved6

Ergocalciferol

Alnylam Pharmaceuticals

Losartan

Organon and Co

Testosterone

Auxilium

Roxadustat

Astellas

Recombinant Human Erythropoietin

Amgen

Analysis

Modality Breakdown

94%

Small molecule

30 of 32 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody13%Peptide13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.

Analysis

Trial Status

39

clinical trials

Completed12 · 31%
Recruiting11 · 28%
Not yet recruiting8 · 21%
Unknown status2 · 5%
Withdrawn2 · 5%
Enrolling by invitation2 · 5%
Other2 · 5%

Clinical Trials

Trial Activity

39 trials

Sarcopenia and Nutritional Status in a Rehabilitation Setting
Recruiting·FFondazione Don Carlo Gnocchi Onlus·N/A·NCT04791540·30 enrolled
Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet
Recruiting·National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland·Phase 2·NCT05978206·168 enrolled
A Study of AMC6156 in People With Sarcopenia
Recruiting·AAnimuscure Inc.·Phase 2·NCT07072195·80 enrolled
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
Recruiting·ZZhejiang Provincial People's Hospital·Phase 4·NCT06537115·450 enrolled
JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
Recruiting·HHospices Civils de Lyon·N/A·NCT05800535·100 enrolled
Morphological and Functional Biomarkers of Skeletal Muscle Adaptations for Early Detection of Sarcopenia and of the Therapeutic Effects of a Home-Based Exercise Intervention: A Randomized-Controlled Trial
Recruiting·—·Preclinical·NCT07692308·192 enrolled
Resveratrol-mediated Changes in Extracellular Vesicle microRNA Cargo as a Novel Contributor to Resistance Training-induced Skeletal Muscle Adaptations in Older Adults
Recruiting·TTexas Tech University·Preclinical·NCT06585865·36 enrolled
The PROTECT Trial Physical Activity and Exercise During Early Treatment for Children With Acute Lymphoblastic Leukaemia to Protect Against Sarcopenia and Improve Frailty Outcomes: a Pilot Randomised Controlled Trial
Recruiting·MMurdoch Childrens Research Institute·Preclinical·NCT07325305·60 enrolled
Effects of Aquatic Exercise Program on Muscle Strength, Muscle Mass, Physical Performance and Quality of Life in Older Adults With Sarcopenia: A Randomized Controlled Trial
Recruiting·GGaziosmanpasa Research and Education Hospital·Preclinical·NCT07575958·44 enrolled
A Multicenter, Prospective, Randomized, Parallel-Group, Double-blinded, Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of a Digital Therapeutic Device for Improving Muscle Strength in Patients With Sarcopenia
Recruiting·EExosystems·Preclinical·NCT07319377·130 enrolled
Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact
Recruiting·NNantes University Hospital·N/A·NCT07004595·100 enrolled
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C
Active, not recruiting·—·Phase 3·NCT03633279·96 enrolled
A Study of PLH-2301 in Subjects With Sarcopenia
Not yet recruiting·PPluto Inc.·Phase 2·NCT07390552·168 enrolled
Impact of Pre-operative Sarcopenia on Functional Recovery After Hip Arthroplasty in Older Adults
Not yet recruiting·UUniversity Hospital, Montpellier·N/A·NCT07429955·20 enrolled
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Not yet recruiting·EEmory University·Phase 3·NCT07428746·20 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)